▼ -100.00% Downside Potential
This price target is based on 6 analysts offering 12 month price targets for Coloplast A/S in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $15.36.
The current consensus among 6 contributing investment analysts is to hold stock in Coloplast A/S. This rating has held steady since March 2020, when it changed from a Sell consensus rating.
Coloplast A/S develops and markets intimate healthcare products and services worldwide. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as SpeediCath catheters that offer catheterization for both genders; Peristeen, an anal irrigation system for controlled emptying of the bowels; and Conveen Active urine bags. In addition, it provides wound care products, such as foam dressings under the Biatain brand and hydrocolloid dressing under the Comfeel brand, as well as skin care products, such as bathing and cleansing products, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Coloplast A/S was founded in 1954 and is headquartered in HumlebÃ¦k, Denmark.